Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025, one of Europe’s leading biotechnology partnering and networking events, hosted by the Swiss Biotech Association.


With thousands of industry professionals expected to attend, this year’s event will spotlight innovation across therapeutic areas,
advanced technologies, and international clinical collaboration.


Representing Richmond Pharmacology at Swiss Biotech Day:

  • Dr Jörg Täubel, Chief Executive Officer
  • Dr Tom Ashdown, Associate Medical Director
  • Stephen Wilkinson, Business Development Manager
  • Amina Senoussi, Key Account Executive


Our team is looking forward to engaging with global biotech leaders and trial sponsors to explore partnerships in:

  • Gene editing and RNA-based therapies
  • Rare and ultra-rare disease research
  • Innovative regulatory pathways
  • Bridging studies
  • Patient-first clinical trial delivery


Whether you're advancing a novel therapy or expanding into new regions, we invite you to visit us at Stand 107 to learn how Richmond Pharmacology can support your trial goals.

For meeting requests or collaboration enquiries, please contact:
info@richmondpharmacology.com

Learn more about the event:

Latest news

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Read more

Upcoming Event

AHA Scientific Sessions 2026

14 - 16 November 2026
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
View event